Novel Therapeutic Technologies

Novel Therapeutic Technologies (NTT) was a biotechnology company specializing in advanced transdermal and topical drug delivery systems. The company's core innovation was the Ethosome™ technology, a patented vesicular carrier system designed to enhance the penetration of drugs through the skin barrier. NTT successfully commercialized several products based on this platform, including Noicellex for cellulite and Nanominox for hair loss. These products were marketed globally in regions such as Japan, the United States, and Europe. Despite its technological successes and significant venture funding, the company reportedly ceased operations in late 2015. NTT remains recognized for its pioneering work in vesicular delivery and its contributions to dermatological aesthetics.